Roche hits back at Novartis with new data for MS drug Ocrevus
US, EU reviews start for Novartis’ Ocrevus rival ofatumumab
Roche raises 2019 outlook, shrugging off biosimilar threat
Addressing MS’ two-tier healthcare system is about ‘social justice’
Roche’s MS drug Ocrevus earns blockbuster status a year after launch
Roche’s MS drug Ocrevus nears European market
Suggestion is that PML case was caused by previous treatment.
Brain infection would be bad news for Roche’s MS drug Ocrevus